BRPI0618643A2 - composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso - Google Patents

composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso Download PDF

Info

Publication number
BRPI0618643A2
BRPI0618643A2 BRPI0618643-2A BRPI0618643A BRPI0618643A2 BR PI0618643 A2 BRPI0618643 A2 BR PI0618643A2 BR PI0618643 A BRPI0618643 A BR PI0618643A BR PI0618643 A2 BRPI0618643 A2 BR PI0618643A2
Authority
BR
Brazil
Prior art keywords
drug
disorder
corticosteroid
disease
composition
Prior art date
Application number
BRPI0618643-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Todd W Chappell
Edward Roydon Jost-Price
Benjamin A Auspitz
Daniel S Grau
Matthew James Nichols
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BRPI0618643A2 publication Critical patent/BRPI0618643A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
BRPI0618643-2A 2005-11-09 2006-11-08 composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso BRPI0618643A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73598905P 2005-11-09 2005-11-09
US60/735,989 2005-11-09
PCT/US2006/043493 WO2007056457A2 (en) 2005-11-09 2006-11-08 Methods, compositions, and kits for the treatment of medical conditions

Publications (1)

Publication Number Publication Date
BRPI0618643A2 true BRPI0618643A2 (pt) 2011-09-06

Family

ID=38023959

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618643-2A BRPI0618643A2 (pt) 2005-11-09 2006-11-08 composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso

Country Status (17)

Country Link
US (4) US20070225217A1 (https=)
EP (2) EP2218442A1 (https=)
JP (2) JP2009514969A (https=)
KR (1) KR20080065704A (https=)
CN (1) CN101355876B (https=)
AR (1) AR058182A1 (https=)
AU (1) AU2006311577B2 (https=)
BR (1) BRPI0618643A2 (https=)
CA (1) CA2628570A1 (https=)
IL (2) IL191283A (https=)
MX (1) MX2008006076A (https=)
NO (1) NO20082473L (https=)
NZ (1) NZ568694A (https=)
RU (1) RU2008122978A (https=)
TW (1) TWI435729B (https=)
WO (1) WO2007056457A2 (https=)
ZA (3) ZA200804550B (https=)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
WO2008022256A2 (en) * 2006-08-16 2008-02-21 Blagosklonny Mikhail V Methods and compositions for preventing or treating age-related diseases
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
US20090088400A1 (en) * 2007-09-11 2009-04-02 Puymirat Jack Prostaglandin e2 modulation and uses thereof
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
JP5670196B2 (ja) * 2007-11-16 2015-02-18 バイセプト セラピューティクス、インク． 紫斑を治療する組成物および方法
US9415036B2 (en) * 2008-02-15 2016-08-16 Bone Therapeutics Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
PT2252290T (pt) 2008-02-15 2018-02-14 Bone Therapeutics Sa Composição farmacêutica para utilização no tratamento e/ou prevenção de doenças osteoarticulares
WO2010006306A1 (en) * 2008-07-10 2010-01-14 Inspire Pharmaceuticals, Inc. Method of treating blepharitis
WO2010025266A1 (en) * 2008-08-27 2010-03-04 University Of Iowa Research Foundation Inhibitors of phosphodiesterase type 5a for treating or preventing muscle disease or the symptoms thereof in a patient
WO2010048264A2 (en) * 2008-10-23 2010-04-29 Combinatorx, Incorporated Methods and compositions for the treatment of immunoinflammatory disorders
WO2010085572A1 (en) * 2009-01-23 2010-07-29 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with azithromycin
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
AU2010233073B2 (en) 2009-04-10 2014-07-31 Haiyan Qi Novel anti-aging agents and methods to identify them
US20110009339A1 (en) * 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US20100279951A1 (en) * 2009-05-01 2010-11-04 Aileen Morgan Method of treating allergic conjunctivitis with cyclosporin compositions
US20120114637A1 (en) * 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
EP2440185B1 (en) * 2009-06-09 2015-04-08 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
RU2407491C1 (ru) * 2009-09-29 2010-12-27 Эрнест Витальевич Бойко Способ лечения внутриглазных инфекций
EP2488642B1 (en) 2009-10-16 2015-03-11 Duke University Compositions and methods for the treatment of drug-induced hand-foot syndrome
LT2493474T (lt) * 2009-10-30 2019-10-10 Intratus, Inc. Būdai ir kompozicijos prolonguotam vaistų įvedimui
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
DE202009017772U1 (de) * 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP2538965B1 (en) * 2010-02-25 2017-04-12 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
WO2012118863A1 (en) * 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Therapies that target autoimmunity for treating glaucoma and optic neuropathy
WO2012149285A1 (en) * 2011-04-28 2012-11-01 Claire Mitchell Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors
US8865685B2 (en) 2011-06-30 2014-10-21 Johnson & Johnson Vision Care, Inc. Esters for treatment of ocular inflammatory conditions
AU2013214693B2 (en) * 2012-02-02 2017-02-23 Kenneth Gek-Jin OOI Improvements in tear film stability
WO2013169315A1 (en) * 2012-05-09 2013-11-14 Hill David W Method for treating macular degeneration
WO2014074995A1 (en) * 2012-11-09 2014-05-15 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability
JP6231857B2 (ja) * 2012-11-13 2017-11-15 徳人 ▲高▼村 眼房水中アルブミンに結合親和性を有する薬剤の効果を増強する眼科用組み合わせ剤
GB201222455D0 (en) * 2012-12-13 2013-01-30 Perioc Ltd Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
WO2014117117A1 (en) * 2013-01-28 2014-07-31 The Johns Hopkins University Chronic nsaid treatment for fuchs endothelial corneal dystrophy
IL225179A (en) * 2013-03-12 2017-01-31 Rogosnitzky Moshe Compounds for use in ocular disorders using dipyridamole
US20150031712A1 (en) 2013-03-12 2015-01-29 Moshe Rogosnitzky Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same
US9254289B2 (en) 2013-03-13 2016-02-09 Remedeye Inc. Methods for treating eye disorders using dipyridamole
US9668996B2 (en) * 2014-06-04 2017-06-06 Tersus Life Sciences, LLC Methods of treating chronic dry eye disease using C16:1n7-palmitoleate and derivatives thereof
US9980976B2 (en) * 2015-02-17 2018-05-29 Northwestern University Use of REDD1 inhibitors to dissociate therapeutic and adverse atrophogenic effects of glucocorticoid receptor agonists
LT3288379T (lt) * 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptidų kompozicijos ir naudojimo būdai
EA201890014A1 (ru) 2015-06-08 2018-07-31 О.Д. Окьюлар Дискавери Лтд. Терапевтические композиции, содержащие дипиридамол, наборы для лечения, содержащие эти композиции, и способы их производства
CA2991195C (en) 2015-07-07 2021-06-29 Codexis, Inc. Novel p450-bm3 variants with improved activity
ES2835274T3 (es) * 2015-07-08 2021-06-22 Axerovision Inc Composiciones farmacéuticas que contienen un antagonista de la integrina alfa 4 para el tratamiento de afecciones inflamatorias oculares
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190008920A1 (en) * 2017-05-19 2019-01-10 Ocugen, Inc. Ophthalmic compositions and methods of use
EP3631462A1 (en) * 2017-05-24 2020-04-08 Koninklijke Philips N.V. Diagnostics of gingivitis based on salivary il-1beta and hgf
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
EP3639854B1 (en) * 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
CN112243375A (zh) * 2018-03-09 2021-01-19 博尔托拉制药公司 选择性syk抑制剂的使用方法及药物组合物
RU2668713C1 (ru) * 2018-03-16 2018-10-02 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ лечения центральных язв роговицы бактериальной и герпетической этиологии
CN109119165A (zh) * 2018-08-27 2019-01-01 珠海为凡医疗信息技术有限公司 一种白内障患病风险检测方法、装置及电子设备
CN111212642A (zh) * 2018-08-29 2020-05-29 奥古根有限公司 眼用组合物及使用方法
US11154540B2 (en) * 2018-10-19 2021-10-26 Medicinova, Inc. Methods of treating ophthalmic disease/disorder or injury with ibudilast
WO2021024041A1 (en) 2019-08-07 2021-02-11 Ripple Therapeutics Corporation Controlled release drug dimers
FR3109524B1 (fr) * 2020-04-22 2022-04-08 H4 Orphan Pharma Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales.
MX2022013665A (es) 2020-05-01 2022-11-30 Ripple Therapeutics Corp Composiciones y metodos heterodimeros para el tratamiento de trastornos oculares.
AU2021345429A1 (en) * 2020-09-21 2023-05-04 Antares Pharma, Inc. Aqueous pharmaceutical formulation of hydrocortisone sodium phosphate and monothioglycerol
US20250275951A1 (en) * 2020-10-30 2025-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drugs targeting inflammation for the treatment of osteoarthritis and other inflammatory diseases
CN116407499B (zh) * 2021-12-29 2024-10-25 辅必成（上海）医药科技有限公司 一种他克莫司眼用乳剂及其制备方法
CA3246335A1 (en) 2022-03-21 2023-09-28 Antares Pharma, Inc. AQUEOUS PHARMACEUTICAL FORMULATION OF SODIUM PHOSPHATE, HYDROCORTISONE AND MONOTHIOGLYCEROL
CN116966187B (zh) * 2022-04-22 2025-11-21 深圳埃格林医药有限公司 地昔帕明前药的新用途

Family Cites Families (392)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US532248A (en) 1895-01-08 powell
US2554736A (en) 1951-05-29 Tertiary aminoalkyl-iminodibenzyls
US3282942A (en) 1966-11-01 Substituted cycloalkanoindoles
US2868818A (en) 1953-12-15 1959-01-13 Merck & Co Inc Alpha methyl phenylalanines
US3046283A (en) 1957-08-19 1962-07-24 Merck & Co Inc 10-(omega-aminoalkylidene)-thioxanthenes
NL110232C (https=) 1958-12-06
US3409640A (en) 1959-07-22 1968-11-05 Schering Corp 5-(3'-dimethylamino-2'-methyl-propyl)dibenzocycloheptenes
NL256053A (https=) 1959-09-22
NL274885A (https=) 1960-09-16
US3454554A (en) 1960-10-14 1969-07-08 Colgate Palmolive Co Aminoalkyliminodibenzyl compounds
FR1332145A (https=) 1961-06-08 1963-12-16
US3158648A (en) 1962-04-09 1964-11-24 Merck & Co Inc Direct resolution of alpha-methyl-3, 4-dihydroxyphenylalanine
US3202660A (en) 1961-10-09 1965-08-24 Boehringer Sohn Ingelheim Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
BE674185A (https=) 1961-10-10
CH426833A (de) 1962-03-27 1966-12-31 Dumex Ltd As Verfahren zur Herstellung des N-Oxyds des N-(3-Dimethylamino-propyl)-iminodibenzyls oder seiner Salze
US3205264A (en) 1962-06-15 1965-09-07 Merck & Co Inc Process for the preparation of 10, 11-dihydro-5-(gamma-methyl-and dimethyl-amino propylidene)-5h-dibenzo[a, d] cycloheptene
US3244748A (en) 1962-07-03 1966-04-05 Merck & Co Inc 5h-dibenzo [a, d] cycloheptenes
US3271451A (en) 1962-07-03 1966-09-06 Merck & Co Inc Process for preparing 5-(3-methylaminopropyl)-5h-dibenzo [a, d] cycloheptenes
US3922305A (en) 1962-08-09 1975-11-25 Merck & Co Inc Chemical compounds
BE636717A (https=) 1962-08-31
US3310553A (en) 1962-09-25 1967-03-21 Pfizer & Co C Alkylated thioxathenesulfonamides
GB991651A (en) 1963-02-20 1965-05-12 Dumex Ltd As Dibenzocycloheptadiene derivatives
US3389139A (en) 1963-06-14 1968-06-18 Wander Ag Dr A 6-homopiperazino and piperazinomorphanthridines
FR88751E (https=) 1963-07-09 1967-06-07
US3981917A (en) 1963-07-25 1976-09-21 Merck & Co., Inc. Chemical compounds
US3978121A (en) 1963-07-25 1976-08-31 Merck & Co., Inc. 5H Dibenzo[a,d]cycloheptene derivatives
US3963778A (en) 1965-11-10 1976-06-15 Bayer Aktiengesellschaft Basic oximes and their preparation
US3505321A (en) 1965-11-24 1970-04-07 Bayer Ag Basically substituted oximes of 5h-dibenzo-(a,d)10,11-dihydro-cycloheptenylidene and their preparation
NL129434C (https=) 1966-03-12
GB1192812A (en) 1966-05-20 1970-05-20 American Cyanamid Co 2-Chloro-11-(1-Piperazinyl)Dibenz[b,f]-[1,4]Oxazepine, Non-Toxic Acid Addition Salts thereof, and Therapeutic Compositions containing said Oxazepine or Salts
FR1532301A (fr) 1967-01-18 1968-07-12 Rhone Poulenc Sa Nouveaux dérivés de la dibenzazépine et leur préparation
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
GB1177525A (en) 1967-04-13 1970-01-14 Leo Ab New Heterocyclic Aminoketones of Therapeutic Interest
CH479559A (de) 1967-09-26 1969-10-15 Wander Ag Dr A Verfahren zur Herstellung von Acylguanidinen
US3892777A (en) 1968-05-01 1975-07-01 Hoffmann La Roche Substituted benzylethylenedicarbamates
US3758528A (en) 1970-03-13 1973-09-11 Science Union & Cie Tricyclic compounds
US4045580A (en) 1971-02-23 1977-08-30 Ciba-Geigy Corporation Pharmaceutical preparation using 9-(2-hydroxy-3-amino-propyl)-9,10-dihydro-9,10-ethano-anthracenes as antidepressants
US4017542A (en) 1971-02-23 1977-04-12 Ciba-Geigy Corporation 9-(2-Hydroxy-3-amino-propyl)-9,10-dihydro-9,10-ethano-anthracenes and salts thereof
US4250094A (en) 1971-04-28 1981-02-10 The Upjohn Company 1-(Aminoalkyl) substituted-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
JPS5229318B2 (https=) 1972-03-30 1977-08-01
CH570401A5 (https=) 1972-05-09 1975-12-15 Wander Ag Dr A
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4020096A (en) 1974-02-01 1977-04-26 Merck & Co., Inc. 10,11,Dihydro-N-alkoxycarbonyl-10,10,11,11-tetrafluoro-5H-dibenzo[a,d]cycloheptene-5-methylamines
US4193926A (en) 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
US4097483A (en) 1974-11-01 1978-06-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolo 1,5-a!pyridines
US4017621A (en) 1974-12-09 1977-04-12 Sumitomo Chemical Company, Limited 2-Morpholinyl tricyclic dibenzazepine compounds
US3956296A (en) 1974-12-11 1976-05-11 A. H. Robins Company, Incorporated 1-Substituted-4-benzylpiperidines
US4224344A (en) 1974-12-13 1980-09-23 Sumitomo Chemical Company, Limited Organic tricyclic compounds
US4358620A (en) 1974-12-13 1982-11-09 Sumitomo Chemical Company, Limited 9-Formyl-9,10-dihydro-9,10-methanoanthracene
NL189199C (nl) 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4048223A (en) 1975-04-11 1977-09-13 Merck & Co., Inc. 3-Dimethylsulfamoyl-5-[amino(alkyl or alkylidene)]-5H-dibenzo [a,d]cycloheptenes
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
JPS527972A (en) 1975-07-07 1977-01-21 Sumitomo Chem Co Ltd Process for preparing novel morpholine derivatives
FR2319333A1 (fr) 1975-07-28 1977-02-25 Roussel Uclaf Nouveaux derives du 7-amino 6,7-dihydro/5h/ benzocycloheptene et leurs sels, procede de preparation et application a titre de medicaments de ces produits
US4128641A (en) 1975-07-31 1978-12-05 Hzi Research Center Inc. Tetracyclic psychotropic drug
GB1531278A (en) 1975-12-15 1978-11-08 Shionogi & Co 9,10-dihydro-9,10-methanoanthracene n-oxide derivatives and the production thereof
US4088647A (en) 1976-02-04 1978-05-09 Glushkov Robert Georgievich Pyrazino (1,2,3-ab)-β-carboline derivatives and salts thereof and method of preparing same
NL7610942A (nl) 1976-10-02 1978-04-04 Akzo Nv Werkwijze voor het bereiden van 1,4-diazepine derivaten.
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
NZ187452A (en) 1977-06-10 1980-05-27 Otsuka Pharma Co Ltd N- substituted-aminocarbonylpropoxy-carbostyrils and their preparation
DE2727481A1 (de) 1977-06-18 1979-01-11 Basf Ag Dihydropyridazone und dihydropyridazone enthaltende therapeutische mittel
CA1114379A (en) 1977-11-03 1981-12-15 Pfizer Corporation Piperidino-phthalazines
FI65914C (fi) 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
NL171194C (nl) 1978-05-23 1983-02-16 Giesen Metaalgieterij Warmwater-ketel, bijvoorbeeld een centrale verwarmingsketel.
US4287175A (en) 1978-06-22 1981-09-01 Merck & Co., Inc. Contact lens wetting agents
DE2837161A1 (de) 1978-08-25 1980-03-06 Thomae Gmbh Dr K Neue benzimidazole und deren verwendung
NL7809726A (nl) 1978-09-26 1980-03-28 Akzo Nv Nieuwe tetracyclische verbindingen.
PH16099A (en) 1979-03-06 1983-06-24 Yamanouchi Pharma Co Ltd Guanidinothiazole compounds,process for preparing them and medical composition containing them
JPS6056143B2 (ja) 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4285958A (en) 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4285957A (en) 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4254130A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
NZ193935A (en) 1979-06-18 1985-05-31 Richardson Merrell Inc 4-aroyl-imidazol-2-one derivatives;pharmaceutical compositions
IL61501A (en) 1979-11-26 1984-06-29 Sterling Drug Inc 5-(pyridinyl)-2(1h)-pyridinones,their preparation and pharmaceutical compositions containing them
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4512978A (en) * 1980-01-24 1985-04-23 Inwood Louis R Dermatological composition useful in the treatment of psoriasis
DE3009034A1 (de) 1980-03-08 1981-09-24 Basf Ag, 6700 Ludwigshafen 10-substituierte 5-cyanmethylendibenzo (a,d) -cycloheptne
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4394508A (en) 1980-06-07 1983-07-19 Bristol-Myers Company Chemical compounds
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
DE3260468D1 (en) 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
US4513002A (en) 1981-01-16 1985-04-23 Hoffmann-La Roche Inc. Cycloheptene derivatives
US4510309A (en) 1981-03-03 1985-04-09 Bristol-Myers Company Histamine H2 -antagonists
US4877805A (en) 1985-07-26 1989-10-31 Kligman Albert M Methods for treatment of sundamaged human skin with retinoids
JPS5851853A (ja) 1981-09-18 1983-03-26 Kyowa Hakko Kogyo Co Ltd リン脂質混合物の処理法
PT75625B (en) 1981-10-08 1985-12-09 Merck & Co Inc Process for preparing biosoluble ocular insert
US4517199A (en) 1981-11-20 1985-05-14 Alcon Laboratories, Inc. Method for lowering intraocular pressure using phenylimino-imidazoles
US4486432A (en) 1982-09-30 1984-12-04 Eli Lilly And Company Quinoxalinedione leukotriene release inhibitors
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
FR2541680B1 (fr) 1983-02-24 1985-06-14 Rhone Poulenc Sante Nouveaux derives de l'amino-5 dithiole-1,2 one-3, leur preparation et les compositions medicinales qui les contiennent
JPS59167590A (ja) 1983-03-14 1984-09-21 Kyorin Pharmaceut Co Ltd ピラゾロ〔１，５−ａ〕ピリジン誘導体、その製法及びそれを含有する治療剤
US4440933A (en) 1983-03-16 1984-04-03 Bristol-Myers Company Process for preparing 1,2,5-thiadiazoles
US4569935A (en) * 1983-03-17 1986-02-11 University Of Tennessee Research Corp. Topical treatment of psoriasis with imidazole antibiotics
US5169637A (en) 1983-03-24 1992-12-08 The Liposome Company, Inc. Stable plurilamellar vesicles
CA1237671A (en) 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
GB8321157D0 (en) 1983-08-05 1983-09-07 Fordonal Sa Piperidine derivatives
GB8400863D0 (en) 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
US4894366A (en) 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US4582822A (en) 1984-10-09 1986-04-15 Eli Lilly And Company Antibiotic A80190, pharmaceutical compositions containing same and method of use
US5254562A (en) 1984-12-03 1993-10-19 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
GB8509276D0 (en) 1985-04-11 1985-05-15 Smith Kline French Lab Pyridine derivatives
US4824863A (en) 1985-05-28 1989-04-25 Eli Lilly And Company Antibiotic A80438
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
US5409704A (en) 1985-06-26 1995-04-25 The Liposome Company, Inc. Liposomes comprising aminoglycoside phosphates and methods of production and use
JPS625963A (ja) 1985-07-02 1987-01-12 Mitsui Toatsu Chem Inc イソキノリン誘導体
US4655074A (en) 1985-08-12 1987-04-07 The Babcock & Wilcox Company Self-zeroing pressure transmitter with automatic pressure manifold
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0220044B1 (en) 1985-10-17 1991-01-30 Smith Kline & French Laboratories Limited 4(4-oxo-1,4-dihydropyridin-1-yl)phenyl derivatives
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5023087A (en) 1986-02-10 1991-06-11 Liposome Technology, Inc. Efficient method for preparation of prolonged release liposome-based drug delivery system
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4742175A (en) 1986-05-07 1988-05-03 Merrell Dow Pharmaceuticals Inc. Preparation of polymorphically pure terfenadine
IE60901B1 (en) 1986-08-21 1994-08-24 Vestar Inc Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics
US5049388A (en) 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
NZ222843A (en) 1986-12-22 1989-10-27 Ortho Pharma Corp Benzoxazinyl- and benzothiazinyl-tetrahydropyridazinones and intermediates, and medicaments
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5272153A (en) 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US4965271A (en) 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
US5032582A (en) 1987-02-27 1991-07-16 Liposome Technology, Inc. Method for treating fungal infections with amphotericin B/cholesterol sulfate composition
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
AU614965B2 (en) 1987-06-06 1991-09-19 Merck Patent Gesellschaft Mit Beschrankter Haftung Thiadiazinones
US4925849A (en) 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
KR920003601B1 (ko) * 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US4839342A (en) * 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US4833138A (en) 1987-10-23 1989-05-23 Washington University Phenothiazinealkaneamines for treatment of neurotoxic injury
ATE110071T1 (de) 1988-01-23 1994-09-15 Kyowa Hakko Kogyo Kk Pyridazinon-derivate und diese enthaltende pharmazeutische zubereitungen.
US5188826A (en) 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
JP2717687B2 (ja) 1988-02-13 1998-02-18 日本曹達株式会社 ピリダジノン誘導体及びその製造方法
US5238959A (en) 1988-04-08 1993-08-24 Eli Lilly And Company 3-phenyloxy-3-phenyl propanamines
US5314875A (en) 1988-05-02 1994-05-24 Eli Lilly And Company Method for treating swine dysentery with the derivatives of the antibiotic A82810
US4994213A (en) 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
US6007840A (en) 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
GB2222770B (en) 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
US4908372A (en) 1988-10-13 1990-03-13 Merrell Dow Pharmaceuticals Inc. Antihistaminic piperidinyl benzimidazoles
GB8827820D0 (en) 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5021410A (en) 1989-05-22 1991-06-04 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
NZ234186A (en) 1989-07-07 1991-10-25 Janssen Pharmaceutica Nv Imidazo quinazolin-one derivatives and pharmaceutical compositions
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
US5112822A (en) 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5326763A (en) 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5198442A (en) 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5077292A (en) 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5208228A (en) 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
US5215991A (en) 1990-01-26 1993-06-01 Allergan, Inc. Combination of selective alpha-adrenergic agonists and Na+ /H+ ex
US5237072A (en) 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5252595A (en) 1990-02-28 1993-10-12 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenylamino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
US5124455A (en) 1990-08-08 1992-06-23 American Home Products Corporation Oxime-carbamates and oxime-carbonates as bronchodilators and anti-inflammatory agents
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5143918A (en) 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
DE4034218A1 (de) 1990-10-27 1992-04-30 Merck Patent Gmbh Verfahren zur herstellung von carebastin
US5141931A (en) 1991-01-03 1992-08-25 Sterling Winthrop Inc. 5-Quinolinylpyridinones, cardiotonic compositions and methods
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
DE69211691T2 (de) 1991-04-19 1997-01-16 Nexstar Pharmaceuticals Inc., Boulder, Col. Pharmazeutische formulierung und pharmazeutisches verfahren
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5262533A (en) 1991-05-13 1993-11-16 Merck & Co., Inc. Amino O-aryl macrolides having immunosuppressive activity
US5162334A (en) 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
IL102236A0 (en) 1991-06-27 1993-01-14 Ltt Inst Co Ltd Topical preparations containing cyclosporin
US5169851A (en) 1991-08-07 1992-12-08 American Home Products Corporation Rapamycin analog as immunosuppressants and antifungals
US5202332A (en) 1991-08-07 1993-04-13 American Home Products Corporation Rapamycin analog as immunosuppressant
GB9216298D0 (en) 1991-08-15 1992-09-16 Ici Plc Piperidine derivatives
US5512575A (en) 1991-08-15 1996-04-30 Zeneca Limited Methanoanthraceneyl methyl piperidinyl compounds
GB9216297D0 (en) 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
US5189042A (en) 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5278150A (en) 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
DE69307505T2 (de) * 1992-05-13 1997-07-24 Sandoz-Patent-Gmbh, 79539 Loerrach Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5284840A (en) 1992-06-12 1994-02-08 Merck & Co., Inc. Alkylidene macrolides having immunosuppressive activity
DE9320925U1 (de) 1992-08-03 1995-08-31 Georgetown University, Washington, D.C. Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
GR1002207B (en) 1992-08-06 1996-03-27 Johnson & Johnson Consumer Skin care compositions containing imidazoles.
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
MY113268A (en) 1992-12-29 2002-01-31 Insite Vision Incorporated Plasticized bioerodible controlled delivery system
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
EP0703902B1 (en) 1993-06-24 1998-12-16 Albany Molecular Research, Inc. Process for the production of piperidine derivatives
US5965595A (en) 1993-07-01 1999-10-12 The Procter & Gamble Company 2-Imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5614627A (en) 1993-09-10 1997-03-25 Eisai Co., Ltd. Quinazoline compounds
US6323204B1 (en) 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
WO1995010280A1 (en) 1993-10-13 1995-04-20 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5580892A (en) 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
US6022852A (en) 1993-10-22 2000-02-08 Hexal Ag Pharmaceutical composition containing cyclosporin A
KR100327264B1 (ko) 1993-10-29 2002-07-02 요시히로 미와 인돌유도체,그의염및이를함유하는심질환치료제
US5464840A (en) 1993-12-06 1995-11-07 Schering Corporation Tricyclic derivatives, compositions and methods of use
US5574173A (en) 1993-12-06 1996-11-12 Schering Corporation Tricyclic derivatives, compositions and methods of use
HU217841B (hu) 1993-12-17 2000-04-28 The Procter & Gamble Co. 6-[(2-Imidazolidinilidén)-amino]-kinolin-származékok és ezeket tartalmazó gyógyszerkészítmények
US5478858A (en) 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5578607A (en) 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5576437A (en) 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
SK77396A3 (en) 1993-12-17 1997-01-08 Procter & Gamble 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6117871A (en) 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
GB9514465D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
CN1046501C (zh) 1994-02-08 1999-11-17 阿尔康实验室公司 新型硫脲复合物及制备硝基芳基亚氨基杂环的方法
CH687062A5 (de) 1994-02-14 1996-09-13 Cerbios Pharma Sa Konzentrierte Injektionsloesung von Alkalimetallsalzen von reduzierten Folaten.
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5773021A (en) 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
EP0775134A4 (en) 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES
WO1996005176A1 (en) 1994-08-09 1996-02-22 Eisai Co., Ltd. Fused pyridazine compound
US5693648A (en) 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
US5545504A (en) 1994-10-03 1996-08-13 Xerox Corporation Ink jettable toner compositions and processes for making and using
US6294563B1 (en) 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
AU3855995A (en) 1994-11-11 1996-06-06 Nippon Soda Co., Ltd. Optically active compound
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5696127A (en) 1994-12-22 1997-12-09 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
CA2189355A1 (en) 1995-03-01 1996-09-06 Yasuo Onoda Imidazoquinazoline derivatives
DE19518082A1 (de) 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
AU5938996A (en) 1995-06-07 1996-12-30 Nexstar Pharmaceuticals, Inc. Method for encapsulating pharmaceutical materials
US5914342A (en) 1995-06-07 1999-06-22 The Procter & Gamble Company 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5856329A (en) 1995-06-28 1999-01-05 Allergan Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5804587A (en) 1995-06-29 1998-09-08 The Procter & Gamble Company 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
DE19537012A1 (de) 1995-10-04 1997-04-10 Dietl Hans Cyclosporin(e) enhaltende pharmazeutische Zubereitung zur oralen Applikation und Verfahren zu ihrer Herstellung
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2175404T3 (es) 1996-05-10 2002-11-16 Icos Corp Derivados de carbolina.
US5709797A (en) 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
WO1998015548A1 (en) 1996-10-04 1998-04-16 Novo Nordisk A/S 1,4-disubstituted piperazines
DE19644228A1 (de) 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
US6306877B1 (en) 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
KR20000069128A (ko) 1996-11-25 2000-11-25 데이비드 엠 모이어 알파-2 아드레날린수용체 아고니스트로서 유용한 2-이미다졸리닐아미노벤즈옥사졸 화합물
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
IL130024A (en) 1996-11-25 2002-12-01 Procter & Gamble Compounds-2 Imidazoline and laminoindole Useful as agonists a - 2 - Adrenoceptors and pharmaceutical preparations containing them
ES2236833T3 (es) 1996-11-25 2005-07-16 THE PROCTER & GAMBLE COMPANY Compuestos heterociclicos de guanidinilo utiles como agonistas de receptores adrenergicos alfa 2.
US5888493A (en) 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
US5837713A (en) * 1997-02-26 1998-11-17 Mayo Foundation For Medical Education And Research Treatment of eosinophil-associated pathologies by administration of topical anesthetics and glucocorticoids
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
EP0977756A1 (en) 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
EP0991660B8 (en) 1997-10-08 2006-04-05 Isotechnika,Inc. DEUTERATED and undeuterated CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US6156753A (en) 1997-10-28 2000-12-05 Vivus, Inc. Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction
SK7792000A3 (en) 1997-11-24 2001-01-18 Procter & Gamble 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability
US6066740A (en) 1997-11-25 2000-05-23 The Procter & Gamble Company Process for making 2-amino-2-imidazoline, guanidine and 2-amino-3,4,5,6-tetrahydropyrimidine derivatives
ES2258300T3 (es) 1997-12-16 2006-08-16 Pfizer Products Inc. Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia.
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
DK1056454T3 (da) 1998-02-23 2003-08-18 Fujisawa Pharmaceutical Co Anvendelse af makrolidforbindelser til behandling af glaukom
TR200003130T2 (tr) 1998-04-28 2001-01-22 Arzneimittelwerk Dresden Gmbh Yeni hidroksiindoller, bunların fosfodiesteraz 4 inhibitörleri olarak kullanımları ve hazırlanmaları için işlemler
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6242442B1 (en) 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
EP1142880A4 (en) 1998-12-24 2002-02-27 Fujisawa Pharmaceutical Co BENZIMIDAZOLE DERIVATIVES
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US20010053780A1 (en) 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
AP1542A (en) 1999-04-30 2006-01-31 Pfizer Prod Inc Glucocorticoid receptor modulators.
US6943166B1 (en) 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
CA2372850C (en) 1999-05-04 2011-01-18 Ulrich Kilian Synergistic combination comprising roflumilast and a pde-3 inhibitor
WO2000068230A1 (en) 1999-05-05 2000-11-16 Darwin Discovery Limited 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors
IT1313583B1 (it) 1999-07-30 2002-09-09 Chiesi Farma Spa Derivati 2-amminotetralinici per la terapia del glaucoma.
US6593480B2 (en) 1999-09-01 2003-07-15 Abbott Laboratories Glucocorticoid receptor antagonists for treatment of diabetes
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US7323496B2 (en) 1999-11-08 2008-01-29 Theracos, Inc. Compounds for treatment of inflammation, diabetes and related disorders
WO2001034632A2 (en) 1999-11-12 2001-05-17 Merck & Co., Inc. Aliphatic hydroxy substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
JP4722360B2 (ja) 1999-11-12 2011-07-13 メルク・シャープ・エンド・ドーム・コーポレイション 抗原虫薬としてのジアリールピペリジルピロール誘導体
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
US6372777B1 (en) 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
EE200200426A (et) 2000-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
US6919337B2 (en) 2000-04-07 2005-07-19 Novartis, Ag 8-Quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
US7019136B2 (en) 2000-04-07 2006-03-28 Novartis, Ag 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as PDE 5 inhibitors
EP1142566B1 (fr) * 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
GB0008694D0 (en) 2000-04-07 2000-05-31 Novartis Ag Organic compounds
NZ522882A (en) 2000-06-05 2004-07-30 Altana Pharma Bv Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors
PL360707A1 (en) 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
BR0113167A (pt) 2000-08-11 2003-06-24 Ono Pharmaceutical Co Derivados de piperidina e agente que compreende o derivado como ingrediente ativo
ATE547080T1 (de) 2000-08-30 2012-03-15 Univ Johns Hopkins Vorrichtungen zur intraokularen arzneimittelabgabe
US6579519B2 (en) 2000-09-18 2003-06-17 Registrar, University Of Delhi Sustained release and long residing ophthalmic formulation and the process of preparing the same
CA2423449A1 (en) 2000-09-26 2002-04-04 The Brigham And Women's Hospital, Inc. Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics
TWI262920B (en) 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
IL180679A0 (en) 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
ES2262612T3 (es) 2000-10-28 2006-12-01 Pfizer Products Inc. Moduladpres del receptor de glucocorticoides.
ATE337320T1 (de) 2000-11-06 2006-09-15 Lilly Icos Llc Indolderivate als pde5-inhibitoren
MXPA03004023A (es) 2000-11-08 2004-02-12 Lilly Icos Llc Compuestos quimicos.
PL362980A1 (en) 2000-11-17 2004-11-02 Warner-Lambert Company Llc Treatment of sexual dysfunction
WO2002060898A1 (en) 2001-01-31 2002-08-08 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
ATE305467T1 (de) 2001-01-31 2005-10-15 Pfizer Prod Inc Als inhibitoren von pde4-isozymen geeignete etherderivate
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
IL156413A0 (en) 2001-01-31 2004-01-04 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
US6583180B2 (en) 2001-02-14 2003-06-24 Abbott Laboratories Glucocorticoid receptor modulators
EE05386B1 (et) 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim
US6617357B2 (en) 2001-03-06 2003-09-09 Smithkline Beecham Corporation Compounds and their use as PDE inhibitors
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
WO2002076953A1 (en) 2001-03-21 2002-10-03 Warner-Lambert Company Llc New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
US6958328B2 (en) 2001-04-18 2005-10-25 Ortho-Mcneil Pharmaceutical, Inc Arylindenopyridines and related therapeutic and prophylactic methods
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
KR20040007596A (ko) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
WO2002098875A1 (en) 2001-06-05 2002-12-12 Lilly Icos Llc Carboline derivatives as pde-5 inhibitors
KR20040010713A (ko) 2001-06-15 2004-01-31 야마노우치세이야쿠 가부시키가이샤 페닐피리딘 카보닐 피페라진 유도체
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
GB0115181D0 (en) 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use
WO2003000691A1 (en) 2001-06-21 2003-01-03 Lilly Icos Llc Carboline derivatives as pdev inhibitors
EP1404330B1 (en) 2001-06-27 2005-06-01 Merck Frosst Canada & Co. Substituted 8-arylquinoline pde4 inhibitors
US6872705B2 (en) 2001-07-13 2005-03-29 Allergan, Inc. Use of antimicrobial peptides as preservatives in ophthalmic preparations, including solutions, emulsions, and suspensions
WO2003012030A2 (en) 2001-08-01 2003-02-13 University Of Utah, Technology Transfer Office Isoform-selective inhibitors and activators of pde3 cyclic
DE10141212A1 (de) 2001-08-22 2003-03-06 Bayer Ag Neue 4-Aminofuropyrimidine und ihre Verwendung
US20030176316A1 (en) 2001-08-24 2003-09-18 Whitehead Clark M. Methods for treatment of rheumatoid arthritis
US6582422B2 (en) 2001-10-03 2003-06-24 Bausch & Lomb Incorporated Ophthalmic delivery device
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
EP1304321A3 (en) 2001-10-17 2003-07-30 Samsung Electronics Co., Ltd. Process for preparing 3-Hydroxyesters from epoxide derivatives
EP1463509A1 (en) * 2001-10-31 2004-10-06 MERCK PATENT GmbH Type 4 phosphodiesterase inhibitors and uses thereof
FR2832711B1 (fr) 2001-11-26 2004-01-30 Warner Lambert Co Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation
JP4745609B2 (ja) 2002-01-22 2011-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用
BR0307595A (pt) 2002-02-07 2005-02-01 Pfizer Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico
KR100698982B1 (ko) 2002-02-11 2007-03-26 화이자 인코포레이티드 Ｐｄｅ4 억제제로서 유용한 니코틴아미드 유도체
EP1476135A1 (en) 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
TWI347845B (en) * 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
EP1348701A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC (2,4-disubstituted-thiazol-5-yl) amine compounds as PDE7 inhibitors
EP1348433A1 (en) 2002-03-28 2003-10-01 Warner-Lambert Company LLC Thiazol-2-yl-imine compounds as PDE-7 inhibitors
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
CA2491836C (en) 2002-07-10 2011-01-25 Arachnova Therapeutics Ltd. 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidine in the treatment of functional bowel disorder
JP4254263B2 (ja) * 2002-08-22 2009-04-15 日産自動車株式会社 ガス流量測定装置及びガス流量測定方法
US20060019932A1 (en) 2002-09-06 2006-01-26 Mancini Joseph A Treatment of rheumatoid arthritis by inhibition of pde4
KR20050043923A (ko) 2002-09-16 2005-05-11 알콘 매뉴팩츄어링, 리미티드 혈관신생 치료를 위한 ｐｄｅ-ⅳ 저해제의 용도
WO2004054501A2 (en) 2002-11-18 2004-07-01 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
US6909002B2 (en) 2002-11-22 2005-06-21 Merck & Co., Inc. Method of preparing inhibitors of phosphodiesterase-4
CA2510296A1 (en) * 2002-12-20 2004-07-15 Control Delivery Systems, Inc. Steroid compositions for intraocular use
WO2004069267A1 (en) * 2003-02-10 2004-08-19 Novartis Ag Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases
WO2004080414A2 (en) * 2003-03-12 2004-09-23 Mullally John P Composition and method for treating inflammations by reducing c-reactive protein
US20040186046A1 (en) 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
EP1613747A1 (en) 2003-03-31 2006-01-11 Pfizer Products Inc. Crystal structure of 3 ,5 -cyclic nucleotide phosphodiesterase 1b (pde1b) and uses thereof
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
AU2004232973A1 (en) 2003-04-18 2004-11-04 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
DE10318611A1 (de) 2003-04-24 2004-11-11 Elbion Ag 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
DE50304744D1 (de) 2003-04-28 2006-10-05 Biofrontera Bioscience Gmbh Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
US20040242673A1 (en) 2003-05-16 2004-12-02 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050112199A1 (en) * 2003-09-24 2005-05-26 Mahesh Padval Therapeutic regimens for administering drug combinations
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
MY141255A (en) 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
JP2007523912A (ja) * 2004-02-26 2007-08-23 アドバンスト アキュラー システムズ リミテッド 眼病変治療用へパリン
EP1737448A1 (en) 2004-03-22 2007-01-03 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
CA2560538A1 (en) 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
EA010834B1 (ru) * 2004-03-29 2008-12-30 Инотек Фармасьютикалз Корпорейшн Пиридилзамещённые порфириновые соединения и способы их применения
US20050234018A1 (en) 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
WO2005107463A1 (en) 2004-05-03 2005-11-17 University Of Virginia Patent Foundation Agonists of a2a adenosine receptors for treatment of diabetic nephropathy
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
DE602004022523D1 (de) * 2004-07-02 2009-09-24 Novagali Pharma Sa Verwendung von Emulsionen zur intra- und periocularen Injection
KR20070042164A (ko) 2004-07-05 2007-04-20 아스텔라스세이야쿠 가부시키가이샤 피라졸로피리딘 유도체
AU2005303893A1 (en) * 2004-11-11 2006-05-18 Argenta Discovery Ltd Pyrimidine compounds as histamine modulators
US20060122152A1 (en) * 2004-12-03 2006-06-08 Peyman Gholam A Heparin for the treatment of ocular pathologies
US20060148686A1 (en) * 2004-12-30 2006-07-06 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
CN103664873B (zh) 2009-12-30 2016-06-15 深圳信立泰药业股份有限公司 作为二肽基肽酶iv(dpp-iv)抑制剂的3-(3-氨基哌啶-1-基)-5-氧代-1,2,4-三嗪衍生物

Also Published As

Publication number Publication date
JP2013231047A (ja) 2013-11-14
IL191283A (en) 2015-03-31
JP5490292B2 (ja) 2014-05-14
TWI435729B (zh) 2014-05-01
AU2006311577A1 (en) 2007-05-18
ZA200804550B (en) 2009-08-26
HK1128593A1 (en) 2009-11-06
KR20080065704A (ko) 2008-07-14
AU2006311577B2 (en) 2013-02-07
US20070105761A1 (en) 2007-05-10
US8067433B2 (en) 2011-11-29
EP1956906A2 (en) 2008-08-20
WO2007056457A3 (en) 2007-09-13
US20120322746A1 (en) 2012-12-20
ZA201201391B (en) 2014-07-30
RU2008122978A (ru) 2009-12-20
EP1956906A4 (en) 2009-12-30
WO2007056457A2 (en) 2007-05-18
CN101355876B (zh) 2012-09-05
IL233634A0 (en) 2014-08-31
US8258153B2 (en) 2012-09-04
AR058182A1 (es) 2008-01-23
CA2628570A1 (en) 2007-05-18
NZ568694A (en) 2011-09-30
ZA200903604B (en) 2012-06-27
TW200803887A (en) 2008-01-16
US20120077756A1 (en) 2012-03-29
MX2008006076A (es) 2008-12-16
US20070225217A1 (en) 2007-09-27
JP2009514969A (ja) 2009-04-09
EP2218442A1 (en) 2010-08-18
NO20082473L (no) 2008-08-06
CN101355876A (zh) 2009-01-28

Similar Documents

Publication Publication Date Title
AU2006311577B2 (en) Methods, compositions, and kits for the treatment of medical conditions
US20050192261A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
ZA200603116B (en) Methods and reagents for the treatment of immunoinflammatory disorders
AU2009324495B2 (en) Methods for treating multiple sclerosis using tetracyclic pyrazinoindoles
US20070213296A1 (en) Compositions and methods for the treatment of immunoinflammatory disorders
US20040224876A1 (en) Combination therapy for the treatment of immunoinflammatory disorders
MX2008014828A (es) Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con niveles incrementados de proteina c-reactiva, interleucina-6 o interferon-gamma.
US20210338642A1 (en) Compositions and methods for the treatment or prevention of pulmonary hypertension
HK1128593B (en) A composition suitable for ophthalmic administration
HK1116675A (en) Methods and reagents for the treatment of immunoinflammatory disorders
ZA200602057B (en) Therapeutic regimens for administering drug combinations
MX2007016114A (en) Combination therapy for the treatment of immunoinflammatory disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.